Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

Naslov

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

Identifikator

/unibl/sci/idNaucniRad:24616

Tip

Datum

Bibliografski citat

S. Cheol Shim, LJ. Božić, A. Berrocal Kasay, E. Chalouhi El-Khouri, F. Irazoque-Palazuelos, F. Fidencio Cons Molina, F. G Medina-Rodriguez, P. Miranda, P. Shesternya, J. Chavez-Corrales, P. Wiland, S. Jeka, O. Garmish, P. Hrycaj, N. Fomina, W. Park, C. Hee Suh, S. Joon Lee, S. Young Lee, Y. Ju Bae, D. Hyun Yoo, Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial, RHEUMATOLOGY, pp. 2193 - 2202, Jun, 2019

Početna stranica

2193

Krajnja stranica

2202

Je dio

RHEUMATOLOGY
1462-0324

Lista autora

Position: 13351 (43 views)